<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439385</url>
  </required_header>
  <id_info>
    <org_study_id>GAIRB2015-87</org_study_id>
    <nct_id>NCT02439385</nct_id>
  </id_info>
  <brief_title>Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis</brief_title>
  <official_title>First Line Avastin/FOLFIRI in Combination With Curcumin-containing Supplement in Colorectal Cancer Patients With Unresectable Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aju Pharm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral curcumin-containing supplement will be given to colorectal cancer patients with
      unresectable metastases who will be starting Avastin/FOLFIRI chemotherapy for up to
      completion of (or withdrawal from) chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The primary end point of this study is to evaluate progression-free survival in colorectal cancer patients with unresectable metastasis after treatment with first line Avastin/FOLFIRI in combination with a dietary supplement of nanostructured lipid curcumin particle (Aju Pharm, Korea), which improved biotransformation and bioavailability profiles of curcumin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (assessed by toxicity grades defined by NCI-CTCAE (version 4.0)</measure>
    <time_frame>2 years</time_frame>
    <description>Safety as assessed by toxicity grades defined by NCI-CTCAE (version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>2 years</time_frame>
    <description>QoL measured by the FACT-G (version 4, Korean version)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue (FACIT-Fatigue scale (version 4, Korean version)</measure>
    <time_frame>2 years</time_frame>
    <description>Fatigue measured by the FACIT-Fatigue scale (version 4, Korean version)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Avastin/FOLFIRI with curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin/FOLFIRI</intervention_name>
    <description>Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.</description>
    <arm_group_label>Avastin/FOLFIRI with curcumin</arm_group_label>
    <other_name>Bevacizumab/FOLFIRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily</description>
    <arm_group_label>Avastin/FOLFIRI with curcumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : 20 Years and older

          -  Histologically confirmed adenocarcinoma of the colon or rectum

          -  Patients with primary colon or rectal cancer and unresectable metastatic lesions.

          -  Patients with no primary cancer related symptoms.

          -  ECOG performance status of 0 - 2

          -  Appropriate organ functions (hepatic transaminases - less than 5 times the normal
             range; bilirubin - less than 2 times the normal range; creatinine serum - less than
             1.5 times the normal range; thrombocyte - more than 100,000/µl; neutrophil - more than
             1,500/µl)

          -  ASA score of &lt; 3

          -  An informed consent form has been signed by the patient.

        Exclusion Criteria:

          -  Colorectal cancer other than adenocarcinoma

          -  The patient received adjuvant chemotherapy within the past 6 months.

          -  The patient received chemotherapy for metastatic colon cancer.

          -  The patient was planning to have curative surgery for the metastatic lesions.

          -  Patients with peritoneal carcinomatosis.

          -  Patients with primary tumor related complications such as intestinal obstruction,
             intractable bleeding, and perforation, that needs to be treated.

          -  ASA score of &gt; 4

          -  The patient has chronic hepatitis or cirrhosis. An asymptomatic HBV or HCV carrier can
             participate.

          -  Patients with an active infection, which need antibiotic therapy, during the
             randomization period.

          -  Pregnant or breastfeeding women

          -  Patients with another different malignant tumor during the past 5 years. Patients with
             treated non-melanoma skin cancer or cervical cancer can be enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Heum Baek, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Jeong-Heum Baek, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>Avastin</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Unresectable metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

